TECX

Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. (TECX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (C-). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.4
EV / EBITDA -2.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -37.5%
Price Return 12M 12.1%
Catalyst Signal 0.00
Market Cap $413.3M
TTM Revenue N/A
Price / Sales N/A
ROE -35.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) C- (2.1) C- (2.0) C- (1.9) C+ (2.6) C (2.2)
2026-11-08 C+ (2.5) C- (2.1) C- (2.0) C- (2.1) C+ (2.6) C (2.3)
2026-11-01 C+ (2.5) C- (2.1) C+ (2.7) C- (2.1) C+ (2.7) C (2.4)
2026-10-25 C+ (2.5) C- (2.1) C+ (2.7) C- (2.1) C+ (2.6) C (2.4)
2026-10-18 C+ (2.5) C- (2.1) C+ (2.7) C (2.3) C+ (2.6) C (2.4)
Page 1 of 3